RT Journal Article SR Electronic T1 Antiangiogenic Effect of KR31372 in Rat Sponge Implant Model JF Journal of Pharmacology and Experimental Therapeutics JO J Pharmacol Exp Ther FD American Society for Pharmacology and Experimental Therapeutics SP 1085 OP 1090 VO 296 IS 3 A1 Chi Dae Kim A1 Hyung Hwan Kim A1 Yong Ki Kim A1 Yong Keun Kwak A1 Sun-Ok Kim A1 Sung-Eun Yoo A1 Ki Whan Hong YR 2001 UL http://jpet.aspetjournals.org/content/296/3/1085.abstract AB A rat sponge implant model was used to examine the antiangiogenic effect of KR31372. Topical administration of angiotensin II (AII, 100 ng, daily) into the sponges enhanced the basal sponge-induced neovascularization, leading to higher clearance of 99mTc, increased retention of dye in the vessels, and increased numbers of blood vessels. These AII-induced changes were significantly suppressed by oral administration of KR31372 (1 mg/kg for 7 days). Angiogenic effect of recombinant human VEGF165 (200 ng) was modestly higher than that of AII, which was also significantly inhibited by KR31372. KR31372-mediated suppression of 99mTc clearance was reversed by glibenclamide. Levcromakalim showed a modestly suppressive effect on the AII-induced angiogenesis. In conclusion, KR31372 exerted a strong inhibitory effect on the sponge-induced neovascularization, in part, through mediation of glibenclamide-sensitive K+ channel activation. It is suggested that it may have therapeutic potential in the treatment of angiogenic disorders. The American Society for Pharmacology and Experimental Therapeutics